|
Sep 30
|
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
|
|
Jul 22
|
Addex’s Partner Discontinues ADX71149 development in Epilepsy
|
|
May 8
|
Addex to Present at Bio€quity Europe 2024
|
|
Apr 29
|
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
|
|
Jan 9
|
Addex to Present at the Swiss Equities Baader Conference
|
|
Dec 20
|
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
|
|
Nov 29
|
Addex Reports Q3 2023 Financial Results and Provides Corporate Update
|
|
Nov 28
|
Addex Convenes Extraordinary General Meeting
|
|
Nov 8
|
Addex Regains Nasdaq Listing Compliance
|
|
Aug 10
|
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
|